HEC Pharm expands Insulin production capacities with Bioengineering

HEC Pharm expands Insulin production capacities with Bioengineering

Bioengineering is pleased to have a strong partnership of many years with HEC Pharm, a leading pharmaceutical company producing innovative medicines, generics, and biologics.
HEC Pharm offers a variety of raw materials and preparations such as recombinant human insulin, insulin glargine, insulin aspart and others to the state government. The product lines include three products and six injections, covering short-acting, medium-acting and long-acting insulin series.The company plans to market these products together with a fourth-generation insulin degludec to the United States by 2024.
With an investment of 740 million RMB, HEC established a production plant in Yichang for the production of Insulin using Pichia Pastoris for high cell density microbial fermentation. Bioengineering was selected as the supplier for Phase 1 and Phase 2, which increases HEC’s production by 8 fermentors for a total increase in capacity of 64,000 L along with their respective seed trains and automation, commissioning and qualification services.

On 24th April 2020, Yichang HEC Pharm started the project with an annual output of 160 million insulin injections.


Wir verwenden Cookies auf unserer Website, um zu verstehen, wie Sie diese nutzen. Indem Sie auf «Zustimmen» klicken, stimmen Sie deren Verwendung zu. Klicken Sie hier, um unsere Datenschutzbestimmungen einzusehen